ArrowMark Partners' Meridian Contrarian Fund outperformed the market in Q4 2024, returning 1.70%. The fund's top holding was Legend Biotech Corporation, a Chinese biotech firm developing a CAR-T cancer drug with Johnson & Johnson, despite facing controversies.